Sheena G Sullivan1, Monique B-N Chilver2, Geoff Higgins3, Allen C Cheng4, Nigel P Stocks2. 1. WHO Collaborating Centre for Reference and Research on Influenza, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC, Australia. sheena.sullivan@influenzacentre.org. 2. Discipline of General Practice, University of Adelaide, Adelaide, SA, Australia. 3. Microbiology and Infectious Diseases, SA Pathology, Adelaide, SA, Australia. 4. Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.
Abstract
OBJECTIVE: To estimate influenza vaccine coverage and effectiveness against medically attended laboratory-confirmed influenza for the 2012 season. DESIGN, SETTING AND PARTICIPANTS: Test-negative design involving patients recruited as part of the Australian Sentinel Practices Research Network, a network of sentinel general practitioners throughout Australia. Throughout 2012, at the discretion of the GP at one of 102 participating practices, patients presenting with influenza-like illness were swabbed and included in the study. MAIN OUTCOME MEASURE: Influenza vaccine effectiveness (VE) estimated as (1-OR)*100% by logistic regression. RESULTS: 1775 patients were swabbed. The epidemic period was identified as Weeks 10 to 43 of 2012. After exclusions, there were 1414 patients for the VE analysis, including 593 (42%) who tested influenza-positive and 821 who tested negative. 27% of test-negative patients were vaccinated, of whom most were aged 50 years and over. The overall VE, adjusted for age group, month of presentation and state or territory, was 23% (95% CI, -4% to 43%) against all influenza types, 15% (95% CI, -17% to 38%) against influenza A, 13% (95% CI, -20% to 36%) against influenza A(not H1) and 53% (95% CI, 5% to 77%) against influenza B. CONCLUSION: Vaccination against influenza was modestly protective, reducing the risk of medical presentation with influenza by around 23%.
OBJECTIVE: To estimate influenza vaccine coverage and effectiveness against medically attended laboratory-confirmed influenza for the 2012 season. DESIGN, SETTING AND PARTICIPANTS: Test-negative design involving patients recruited as part of the Australian Sentinel Practices Research Network, a network of sentinel general practitioners throughout Australia. Throughout 2012, at the discretion of the GP at one of 102 participating practices, patients presenting with influenza-like illness were swabbed and included in the study. MAIN OUTCOME MEASURE: Influenza vaccine effectiveness (VE) estimated as (1-OR)*100% by logistic regression. RESULTS: 1775 patients were swabbed. The epidemic period was identified as Weeks 10 to 43 of 2012. After exclusions, there were 1414 patients for the VE analysis, including 593 (42%) who tested influenza-positive and 821 who tested negative. 27% of test-negative patients were vaccinated, of whom most were aged 50 years and over. The overall VE, adjusted for age group, month of presentation and state or territory, was 23% (95% CI, -4% to 43%) against all influenza types, 15% (95% CI, -17% to 38%) against influenza A, 13% (95% CI, -20% to 36%) against influenza A(not H1) and 53% (95% CI, 5% to 77%) against influenza B. CONCLUSION: Vaccination against influenza was modestly protective, reducing the risk of medical presentation with influenza by around 23%.
Authors: Huiying Chua; Shuo Feng; Joseph A Lewnard; Sheena G Sullivan; Christopher C Blyth; Marc Lipsitch; Benjamin J Cowling Journal: Epidemiology Date: 2020-01 Impact factor: 4.822
Authors: Michael L Jackson; Jill Ferdinands; Mary Patricia Nowalk; Richard K Zimmerman; Burney Kieke; Manjusha Gaglani; Kempapura Murthy; Joshua G Petrie; Emily T Martin; Jessie R Chung; Brendan Flannery; Lisa A Jackson Journal: BMC Public Health Date: 2021-03-16 Impact factor: 3.295
Authors: Zoe Patterson Ross; Naomi Komadina; Yi-Mo Deng; Natalie Spirason; Heath A Kelly; Sheena G Sullivan; Ian G Barr; Edward C Holmes Journal: PLoS Pathog Date: 2015-06-24 Impact factor: 6.823
Authors: S G Sullivan; K S Carville; M Chilver; J E Fielding; K A Grant; H Kelly; A Levy; N P Stocks; S S Tempone; A K Regan Journal: Epidemiol Infect Date: 2016-04-29 Impact factor: 4.434